ReviewClinical microbiology reviews2005
Novel perspectives on mucormycosis: pathophysiology, presentation, and management.
Review in Clinical microbiology reviews, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00419770 (The Deferasirox-AmBisome Therapy for Mucormycosis), which is not on this map. Cited by 579 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Who cites it
579 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,503 citations in OpenAlex.
- Mucormycosis in Paediatric Patients After Haematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.Mycoses · 2025Pooled it
- Evolutionary trends in antifungal resistance: a meta-analysis.Microbiology spectrum · 2024Pooled it
- COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Pooled it
- A retrospective analysis for the management of oromaxillofacial invasive mucormycosis and systematic literature review.BMC oral health · 2023Pooled it
- The outcome and the risk factors of mucormycosis among patients with hematological diseases: a systematic and meta-analysis.Frontiers in medicine · 2023Pooled it
- Diagnostic Challenges of Non-Sporulating Fungal Isolates Recovered from Traumatic Wounds Following Motor Vehicle Collisions:Journal of fungi (Basel, Switzerland) · 2026Article
- Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis.Journal of fungi (Basel, Switzerland) · 2026Article
- "Adjunctive topical amphotericin B in post-transplant surgical-site mucormycosis in an immunocompromised diabetic patient: a case report".Annals of medicine and surgery (2012) · 2026Article
- Multimodal non-surgical management of isolated tracheobronchial mucormycosis: a case series of 8 patients.BMC infectious diseases · 2026Article
- Severe angioinvasive pulmonary mucormycosis in an immunocompetent patient with poorly controlled diabetes: a case report.Journal of medical case reports · 2026Article
- Dynamic Reprogramming of Fungal Cell Walls Underlies Germination and Immune Exposure in Zygomycetous Fungal Pathogens.bioRxiv : the preprint server for biology · 2026Article
- Towards accurate genomic detection of fungal antimicrobial resistance: progress in fungal resistance databases and bioinformatic tools.Microbial genomics · 2026Review
- Article
- Retrospective Evaluation of Mucormycosis Cases at a Tertiary Care Center Between 2000 and 2020 in Türkiye.Mycopathologia · 2026Article
- Rapid and reliable diagnosis of mucormycosis using colorimetric loop-mediated isothermal amplification.Journal of clinical microbiology · 2026Article
- All That Swells Is Not Allergy: Unmasking Rhino-Orbital-Cerebral Mucormycosis in Diabetic Ketoacidosis.Cureus · 2026Article
- Article
- A Rare Case of Cutaneous Mucormycosis byClinical case reports · 2026Article
- Article
- Epidemiological profile and clinical outcomes of patients with mucormycosis: the multicenter retromucor study from Türkiye (2004-2024).European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
519 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis is a life-threatening fungal infection that occurs in immunocompromised patients. These infections are becoming increasingly common, yet survival remains very poor. A greater understanding of the pathogenesis of the disease may lead to future therapies. For example, it is now clear that iron metabolism plays a central role in regulating mucormycosis infections and that deferoxamine predisposes patients to mucormycosis by inappropriately supplying the fungus with iron. These findings raise the possibility that iron chelator therapy may be useful to treat the infection as long as the chelator does not inappropriately supply the fungus with iron. Recent data support the concept that high-dose liposomal amphotericin is the preferred monotherapy for mucormycosis. However, several novel therapeutic strategies are available. These options include combination therapy using lipid-based amphotericin with an echinocandin or with an azole (largely itraconazole or posaconazole) or with all three. The underlying principles of therapy for this disease remain rapid diagnosis, reversal of underlying predisposition, and urgent surgical debridement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.